REDUCE-IT Clinical Trial Results Presented and Published

Dr. Frank McGrew and The Stern Cardiovascular Foundation had the pleasure of participating in the REDUCE-IT clinical trial, a placebo-controlled trial to study the effects of icosapent ethyl (Vascepa) in patients with established cardiovascular disease or diabetes and an elevated fasting triglyceride level. Thanks to the generosity of our volunteer subjects, the study completed its enrollment of 8179 patients around the world and was able to follow the patients for almost 5 years. On November 10, 2018, the results of this study were presented at the American Heart Association annual meeting and published simultaneously in The New England Journal of Medicine. Thanks to the thousands of volunteers, it was determined that for patients with elevated triglyceride levels, the risk of ischemic events was significantly lowered amount subjects receiving icosapent ethyl. The study drug, also known as Vascepa, is approved for use in the United States and can be prescribed by your physician at Stern Cardiovascular.

Read the full publication on Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia in the New England Journal of Medicine.